Literature DB >> 32301174

Motion correction in magnetic resonance spectroscopy.

Muhammad G Saleh1,2, Richard A E Edden1,2, Linda Chang3, Thomas Ernst3.   

Abstract

In vivo proton magnetic resonance spectroscopy and spectroscopic imaging (MRS/MRSI) are valuable tools to study normal and abnormal human brain physiology. However, they are sensitive to motion, due to strong crusher gradients, long acquisition times, reliance on high magnetic field homogeneity, and particular acquisition methods such as spectral editing. The effects of motion include incorrect spatial localization, phase fluctuations, incoherent averaging, line broadening, and ultimately quantitation errors. Several retrospective methods have been proposed to correct motion-related artifacts. Recent advances in hardware also allow prospective (real-time) correction of the effects of motion, including adjusting voxel location, center frequency, and magnetic field homogeneity. This article reviews prospective and retrospective methods available in the literature and their implications for clinical MRS/MRSI. In combination, these methods can attenuate or eliminate most motion-related artifacts and facilitate the acquisition of high-quality data in the clinical research setting.
© 2020 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  MRS; MRSI; motion; navigated spectroscopy sequence; prospective correction; retrospective correction

Mesh:

Year:  2020        PMID: 32301174      PMCID: PMC8386494          DOI: 10.1002/mrm.28287

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   3.737


  119 in total

1.  Restoration of motion-related signal loss and line-shape deterioration of proton MR spectra using the residual water as intrinsic reference.

Authors:  G Helms; A Piringer
Journal:  Magn Reson Med       Date:  2001-08       Impact factor: 4.668

2.  Regularized higher-order in vivo shimming.

Authors:  Dong-Hyun Kim; Elfar Adalsteinsson; Gary H Glover; Daniel M Spielman
Journal:  Magn Reson Med       Date:  2002-10       Impact factor: 4.668

Review 3.  Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts.

Authors:  Roland Kreis
Journal:  NMR Biomed       Date:  2004-10       Impact factor: 4.044

4.  Prospective correction of affine motion for arbitrary MR sequences on a clinical scanner.

Authors:  Kay Nehrke; Peter Börnert
Journal:  Magn Reson Med       Date:  2005-11       Impact factor: 4.668

5.  Direct in vivo measurement of human cerebral GABA concentration using MEGA-editing at 7 Tesla.

Authors:  Melissa Terpstra; Kamil Ugurbil; Rolf Gruetter
Journal:  Magn Reson Med       Date:  2002-05       Impact factor: 4.668

6.  Simultaneous in vivo spectral editing and water suppression.

Authors:  M Mescher; H Merkle; J Kirsch; M Garwood; R Gruetter
Journal:  NMR Biomed       Date:  1998-10       Impact factor: 4.044

7.  Altered neurotransmitter metabolism in adolescents with high-functioning autism.

Authors:  Gerhard S Drenthen; Evelien M Barendse; Albert P Aldenkamp; Tamar M van Veenendaal; Nicolaas A J Puts; Richard A E Edden; Svitlana Zinger; Geert Thoonen; Marc P H Hendriks; Roy P C Kessels; Jacobus F A Jansen
Journal:  Psychiatry Res Neuroimaging       Date:  2016-09-20       Impact factor: 2.376

8.  Impulsiveness and cigarette smoking.

Authors:  Janine D Flory; Stephen B Manuck
Journal:  Psychosom Med       Date:  2009-02-27       Impact factor: 4.312

9.  Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis.

Authors:  Sara Llufriu; John Kornak; Helene Ratiney; Joonmi Oh; Don Brenneman; Bruce A Cree; Mehul Sampat; Stephen L Hauser; Sarah J Nelson; Daniel Pelletier
Journal:  JAMA Neurol       Date:  2014-07-01       Impact factor: 18.302

10.  Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.

Authors:  Ian Marshall; Michael J Thrippleton; Mark E Bastin; Daisy Mollison; David A Dickie; Francesca M Chappell; Scott I K Semple; Annette Cooper; Sue Pavitt; Gavin Giovannoni; Claudia A M Gandini Wheeler-Kingshott; Bhavana S Solanky; Christopher J Weir; Nigel Stallard; Clive Hawkins; Basil Sharrack; Jeremy Chataway; Peter Connick; Siddharthan Chandran
Journal:  J Neurol       Date:  2018-05-30       Impact factor: 4.849

View more
  3 in total

1.  In vivo spectral editing of phosphorylethanolamine.

Authors:  Steve C N Hui; Helge J Zöllner; Georg Oeltzschner; Richard A E Edden; Muhammad G Saleh
Journal:  Magn Reson Med       Date:  2021-08-19       Impact factor: 4.668

2.  Does the change in glutamate to GABA ratio correlate with change in depression severity? A randomized, double-blind clinical trial.

Authors:  G Anjali Narayan; Kathryn R Hill; Kenneth Wengler; Xiang He; Junying Wang; Jie Yang; Ramin V Parsey; Christine DeLorenzo
Journal:  Mol Psychiatry       Date:  2022-08-18       Impact factor: 13.437

3.  Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.

Authors:  Jason Smucny; Cameron S Carter; Richard J Maddock
Journal:  Biol Psychiatry       Date:  2021-06-12       Impact factor: 12.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.